Arcutis Biotherapeutics (NASDAQ:ARQT) Posts Quarterly Earnings Results, Misses Expectations By $0.12 EPS

Arcutis Biotherapeutics (NASDAQ:ARQT) posted its quarterly earnings results on Wednesday. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.12), FiscalAI reports. Arcutis Biotherapeutics had a net margin of 5.88% and a return on equity of 14.96%. The firm had revenue of $143.92 million for the quarter, compared to analyst estimates of $142.59 million.

Here are the key takeaways from Arcutis Biotherapeutics’ conference call:

• Revenue growth remained strong: Third-quarter net product revenue was $143.9 million, up 45% year over year and 11% sequentially. ZORYVE demand exceeded 300,000 prescriptions, with growth across all indications and formulations.
• 2026 revenue guidance was raised to $535 million-$545 million from $525 million-$540 million, reflecting Q3 strength and management’s outlook for continued demand growth.
• SG&A expense rose 60% year over year to $99.6 million, driven by advertising and sales-force expansion; the company expects spending to remain elevated in Q4 as it invests for future growth. Arcutis reported $8.8 million in net income and $18.9 million in positive operating cash flow for the quarter.
• Several pipeline catalysts are approaching, including a Q4 2026 readout from the vitiligo proof-of-concept trial, expected HS results in Q1 2027, and a February 23, 2027 PDUFA date for ZORYVE in infants with atopic dermatitis. These programs remain subject to clinical results and, where applicable, regulatory decisions.

Arcutis Biotherapeutics Stock Down 20.7%

Shares of Arcutis Biotherapeutics stock opened at $27.00 on Friday. Arcutis Biotherapeutics has a twelve month low of $19.30 and a twelve month high of $34.80. The stock has a market capitalization of $3.39 billion, a price-to-earnings ratio of 128.58 and a beta of 1.66. The company has a current ratio of 2.92, a quick ratio of 2.67 and a debt-to-equity ratio of 0.46. The business’s 50 day simple moving average is $27.15 and its 200-day simple moving average is $25.37.

Insider Activity

In other Arcutis Biotherapeutics news, insider Patrick Burnett sold 8,300 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $26.52, for a total value of $220,116.00. Following the sale, the insider directly owned 119,289 shares of the company’s stock, valued at $3,163,544.28. This trade represents a 6.51% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Todd Watanabe sold 4,377 shares of the firm’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $31.86, for a total value of $139,451.22. Following the completion of the sale, the insider owned 712,826 shares in the company, valued at $22,710,636.36. The trade was a 0.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 123,932 shares of company stock worth $3,553,077 over the last 90 days. Insiders own 9.40% of the company’s stock.

Key Stories Impacting Arcutis Biotherapeutics

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Arcutis began enrolling participants in a Phase 3 trial of ZORYVE cream 0.3% for moderate-to-severe atopic dermatitis. Success could expand the treatment’s use and address a broader patient population, though the study is an early-stage catalyst rather than near-term revenue. Phase 3 study announcement
• Positive Sentiment: Third-quarter revenue was $143.92 million, modestly ahead of the approximately $142.6 million analyst consensus, providing a partial offset to the earnings miss. Quarterly earnings report
• Neutral Sentiment: Rob Lisicki was appointed chief commercial officer, effective November 4. The leadership change may support commercial execution, but its impact on sales remains to be seen. Chief commercial officer appointment
• Neutral Sentiment: Several executives reported share sales, including a larger sale by EVP Masaru Matsuda under a pre-arranged trading plan. Some reported transactions were to cover tax withholding on vested equity awards, which makes them less clearly bearish, though insider selling may attract investor attention. SEC insider filing
• Negative Sentiment: Third-quarter earnings were $0.06 per share, well below analysts’ estimates of roughly $0.17–$0.18 and unchanged from a year earlier. The earnings miss was the clearest near-term pressure on the stock, despite the modest revenue beat. Report on the earnings miss

Analyst Upgrades and Downgrades

Several research firms have weighed in on ARQT. Cantor Fitzgerald started coverage on shares of Arcutis Biotherapeutics in a research note on Thursday, October 15th. They set an “overweight” rating and a $48.00 target price for the company. Wall Street Zen cut shares of Arcutis Biotherapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, October 10th. Weiss Ratings upgraded shares of Arcutis Biotherapeutics from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, October 29th. Jefferies Financial Group restated a “buy” rating and issued a $39.00 price target on shares of Arcutis Biotherapeutics in a research report on Thursday, October 8th. Finally, TD Cowen lifted their price target on shares of Arcutis Biotherapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a report on Thursday. Eight investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $39.75.

Arcutis Biotherapeutics Company Profile

Arcutis Biotherapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering treatments for dermatologic conditions. The company’s portfolio is centered on therapies designed to address inflammatory skin diseases, with an emphasis on nonsteroidal topical medicines that may help patients manage chronic conditions.

Arcutis’s lead product is ZORYVE (roflumilast), a topical phosphodiesterase-4 inhibitor. ZORYVE has received U.S. Food and Drug Administration approvals for multiple dermatological uses, including plaque psoriasis, seborrheic dermatitis and atopic dermatitis, in different cream and foam formulations.